Yuhan Corporation Receives $30 Million Milestone for Reklyza Launch in Europe

Accumulated Milestones Reach $300 Million, Securing One-Third of Total Contract Value
Expansion into Europe Following the U.S., Japan, and China
Global Sales Expected to Grow Further

Yuhan Corporation will receive a milestone payment for the commercialization of Reklyza (ingredient: lazertinib), a treatment for non-small cell lung cancer, in Europe.

Reclaza product image. Yuhan Corporation

On May 14, Yuhan Corporation announced that it will receive 30 million dollars (approximately 44.7 billion won) from its global partner Janssen Biotech for the launch of the lazertinib and amivantamab combination therapy in Europe.

With this milestone, the total accumulated milestones Yuhan Corporation has secured for lazertinib, including the upfront payment, have increased to 300 million dollars (approximately 447 billion won).

In November 2018, Yuhan Corporation out-licensed lazertinib to Janssen and received an upfront payment of 50 million dollars (approximately 74.5 billion won). Since then, it received 35 million dollars (52.1 billion won) as the combination therapy development progressed and 65 million dollars (approximately 96.8 billion won) upon the initiation of phase 3 clinical trials. At the commercialization stage, Yuhan Corporation received 60 million dollars (approximately 89.4 billion won) for the U.S. launch, 15 million dollars (approximately 22.4 billion won) for Japan, 45 million dollars (approximately 67.1 billion won) for China, and has now additionally secured 30 million dollars (approximately 44.7 billion won) for Europe.

The total milestone payments available under the entire contract, including the upfront payment, amount to 950 million dollars (approximately 1.416 trillion won). Yuhan Corporation has now secured about one-third of this amount.

Yuhan Corporation is also receiving royalty income. As the sales regions for the lazertinib and amivantamab combination therapy expand from the United States to Japan, China, and now Europe, royalty revenues are also expected to increase.

Reklyza is an EGFR-mutant non-small cell lung cancer treatment. Last year, it was listed as the preferred first-line treatment (Category 1) in the U.S. National Comprehensive Cancer Network (NCCN) guidelines.

This content was produced with the assistance of AI translation services.